$1.35
▼ -0.3% Today
as of Sep 4, 16:53 ET
Last 30 days
Recent Press Releases & News
Pacific Biosciences (PACB) Up 11.6% Since Last Earnings Report: Can It Continue?
PACB Cuts 2026 Outlook as Clinical Adoption Faces Its Crucial Test
3 Reasons to Sell PACB and 1 Stock to Buy Instead
Overview
52-week range
$1.07
$2.73
17% of range
Avg surprise (last 3)
+26.1%
Avg reaction (last 2)
+1.3%
50% positive
Latest IV / EM
190%
EM ±29.6% · $2 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-0.14 | — | — | — | — | financials |
| Thu May 7, 2026 | Mar/2026 | $-0.12 | $-0.17 | +29.4% | +20.0% | -3.5% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.13 | — | — | — | — | financials |
| Thu Aug 7, 2025 | Jun/2025 | $-0.13 | $-0.18 | +27.8% | — | — | earnings |
| Thu May 8, 2025 | Mar/2025 | $-0.15 | $-0.19 | +21.1% | — | +6.2% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.22 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.64 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.29 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.26 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.28 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-0.36 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $39M | $37M | — | $38M | $40M | $37M | — | $40M |
| Cost of revenue | $26M | $24M | — | $23M | $25M | $39M | — | $30M |
| Gross profit | $13M | $13M | — | $16M | $15M | $-1M | — | $10M |
| Operating income | $-45M | $-8M | — | $-39M | $-45M | $-429M | — | $-64M |
| Net income | $-45M | $-8M | — | $-38M | $-42M | $-426M | — | $-61M |
| EPS (diluted) | $-0.14 | $-0.03 | — | $-0.13 | $-0.14 | $-1.44 | — | $-0.22 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $61M | $56M | $64M | $56M | $55M | $59M | $55M | $78M |
| Inventory | $61M | $51M | $49M | $53M | $54M | $54M | $59M | $66M |
| Total current assets | $339M | $370M | $375M | $394M | $413M | $445M | $496M | $584M |
| Total assets | $752M | $782M | $784M | $803M | $825M | $861M | $1.26B | $1.45B |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $785M | $780M | $779M | $767M | $764M | $769M | $754M | $997M |
| Total equity | $-33M | $2M | $5M | $36M | $61M | $92M | $507M | $453M |